Literature DB >> 21195536

Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.

Louise Dickinson1, Hashim U Ahmed, Clare Allen, Jelle O Barentsz, Brendan Carey, Jurgen J Futterer, Stijn W Heijmink, Peter J Hoskin, Alex Kirkham, Anwar R Padhani, Raj Persad, Philippe Puech, Shonit Punwani, Aslam S Sohaib, Bertrand Tombal, Arnauld Villers, Jan van der Meulen, Mark Emberton.   

Abstract

BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) may have a role in detecting clinically significant prostate cancer in men with raised serum prostate-specific antigen levels. Variations in technique and the interpretation of images have contributed to inconsistency in its reported performance characteristics.
OBJECTIVE: Our aim was to make recommendations on a standardised method for the conduct, interpretation, and reporting of prostate mpMRI for prostate cancer detection and localisation. DESIGN, SETTING, AND PARTICIPANTS: A consensus meeting of 16 European prostate cancer experts was held that followed the UCLA-RAND Appropriateness Method and facilitated by an independent chair. MEASUREMENT: Before the meeting, 520 items were scored for "appropriateness" by panel members, discussed face to face, and rescored. RESULTS AND LIMITATIONS: Agreement was reached in 67% of 260 items related to imaging sequence parameters. T2-weighted, dynamic contrast-enhanced, and diffusion-weighted MRI were the key sequences incorporated into the minimum requirements. Consensus was also reached on 54% of 260 items related to image interpretation and reporting, including features of malignancy on individual sequences. A 5-point scale was agreed on for communicating the probability of malignancy, with a minimum of 16 prostatic regions of interest, to include a pictorial representation of suspicious foci. Limitations relate to consensus methodology. Dominant personalities are known to affect the opinions of the group and were countered by a neutral chairperson.
CONCLUSIONS: Consensus was reached on a number of areas related to the conduct, interpretation, and reporting of mpMRI for the detection, localisation, and characterisation of prostate cancer. Before optimal dissemination of this technology, these outcomes will require formal validation in prospective trials.
Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21195536     DOI: 10.1016/j.eururo.2010.12.009

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  201 in total

1.  [Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy].

Authors:  C Arsov; D Blondin; R Rabenalt; G Antoch; P Albers; M Quentin
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

Review 2.  Image guidance in the focal treatment of prostate cancer.

Authors:  Anthony N Hoang; Dmitry Volkin; Nitin K Yerram; Srinivas Vourganti; Jeffrey Nix; W Marston Linehan; Bradford Wood; Peter A Pinto
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

3.  Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database.

Authors:  D Gabriele; D Collura; M Oderda; I Stura; C Fiorito; F Porpiglia; C Terrone; M Zacchero; C Guiot; P Gabriele
Journal:  World J Urol       Date:  2015-08-15       Impact factor: 4.226

4.  Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance.

Authors:  Iqbal Sahibzada; Deepak Batura; Giles Hellawell
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

5.  Prostate cancer: The applicability of textural analysis of MRI for grading.

Authors:  Frederick Kelcz; David F Jarrard
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

6.  Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy.

Authors:  Michael Quentin; Lars Schimmöller; Christian Arsov; Robert Rabenalt; Gerald Antoch; Peter Albers; Dirk Blondin
Journal:  Eur Radiol       Date:  2013-08-31       Impact factor: 5.315

7.  Preliminary experience with a novel method of three-dimensional co-registration of prostate cancer digital histology and in vivo multiparametric MRI.

Authors:  C Orczyk; H Rusinek; A B Rosenkrantz; A Mikheev; F-M Deng; J Melamed; S S Taneja
Journal:  Clin Radiol       Date:  2013-08-28       Impact factor: 2.350

8.  Can 3T multiparametric magnetic resonance imaging accurately detect prostate cancer extracapsular extension?

Authors:  Yannick Cerantola; Massimo Valerio; Aida Kawkabani Marchini; Jean-Yves Meuwly; Patrice Jichlinski
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

9.  The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer.

Authors:  François Marliere; Philippe Puech; Ahmed Benkirane; Arnauld Villers; Laurent Lemaitre; Xavier Leroy; Nacim Betrouni; Adil Ouzzane
Journal:  World J Urol       Date:  2014-05-12       Impact factor: 4.226

10.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.